10-Q: Synergy CHC Q3 2025: Revenue Up, Debt Reduced, IPO Boosts Capital

Synergy CHC Corp. reported increased Q3 revenue and gross profit, significantly reduced liabilities through debt settlements and a new senior loan, and completed an IPO.

Summary

• Q3 2025 revenue increased to $8.01 million from $7.13 million in Q3 2024, primarily due to a packaging upgrade delay in 2024 not repeating.
• Nine-month 2025 revenue was $24.32 million, slightly down from $24.56 million in 2024, as a new product sell-in in 2024 did not repeat, but was offset by $2.9 million in new license revenue.
• Gross profit margin improved to 71% in Q3 2025 (from 67% in Q3 2024) and to 74% for the nine months (from 70% in 2024), driven by product mix and license revenue.
• Net income for Q3 2025 decreased to $125,327 from $783,593 in Q3 2024, due to higher expenses and other income in 2024 not repeating.
• Net income for the nine months ended September 30, 2025, increased to $2.47 million from $2.02 million in 2024, primarily due to significant gains on loan settlements.
• Total liabilities decreased significantly to $28.94 million as of September 30, 2025, from $32.97 million at December 31, 2024, largely due to debt repayments and settlements.
• Total stockholders' deficit improved to $(8.25) million from $(16.63) million, reflecting a stronger equity position.
• Cash and cash equivalents increased to $1.01 million from $687,920.
• Net cash used in operating activities increased to $(3.21) million for the nine months, while net cash provided by financing activities significantly increased to $3.52 million, driven by new loans and an IPO.
• The company completed an IPO on August 27, 2025, selling 1,750,000 shares at $2.50 per share, generating net proceeds of $3.88 million for working capital and general corporate purposes.
• Significant debt settlements occurred, including a $12.71 million loan with Knight Therapeutics and loans with former suppliers, resulting in substantial gains.

Sentiment

Score: 6

Explanation: The company showed significant improvements in its balance sheet by reducing liabilities and improving stockholders' deficit, largely due to successful debt settlements and a capital raise through an IPO. However, the decrease in Q3 net income, increased operating cash burn, and the acknowledged ineffectiveness of disclosure controls temper the overall positive sentiment.

Positives

• Increased Q3 2025 revenue to $8.01 million from $7.13 million in Q3 2024.
• Improved gross profit margin to 71% in Q3 2025 and 74% for the nine months ended September 30, 2025.
• Nine-month net income increased to $2.47 million in 2025 from $2.02 million in 2024, driven by gains on loan settlements.
• Significant reduction in total liabilities to $28.94 million from $32.97 million.
• Substantial improvement in stockholders' deficit, reducing it from $(16.63) million to $(8.25) million.
• Successful completion of an Initial Public Offering (IPO) on August 27, 2025, raising $3.88 million in net proceeds.
• Secured a new $17.5 million term loan facility with ACP Agency, LLC, providing capital for debt repayment and working capital.
• Successfully settled several significant loans, including a $12.71 million loan with Knight Therapeutics, resulting in a gain of $1.81 million.
• Introduced $2.9 million in new license revenue for the nine months ended September 30, 2025.
• Online sales channel showed strong growth, increasing to $7.05 million for the nine months ended September 30, 2025, from $5.78 million in 2024.
• Expansion into Mexico with the incorporation of Synergy CHC Mexico in May 2025.

Negatives

• Q3 2025 net income significantly decreased to $125,327 from $783,593 in Q3 2024, primarily due to higher expenses and non-recurring other income in the prior year.
• Nine-month 2025 nutraceuticals product sales decreased to $21.42 million from $24.56 million in 2024, attributed to a non-repeating new product sell-in to a customer in 2024.
• General and administrative expenses increased for both the three and nine months ended September 30, 2025, primarily due to public market expenses.
• Interest expense significantly increased for both the three and nine months ended September 30, 2025, due to new loans and amortization of original debt discount.
• Net cash used in operating activities increased to $(3.21) million for the nine months ended September 30, 2025, from $(1.38) million in 2024.
• Disclosure controls and procedures were deemed "not effective" as of September 30, 2025.
• High concentration of credit risk with a few major customers (3 customers accounted for 80% of net revenue for nine months ended Sep 30, 2025) and suppliers (2 suppliers accounted for 42% of purchases for nine months ended Sep 30, 2025).
• Loan receivable from a related party (company owned by CEO Jack Ross) of $4.41 million is due by December 31, 2025, with a pledge of borrower's stock as security if not repaid.

Risks

• Disclosure controls and procedures were not effective as of September 30, 2025, which could impact the reliability of financial reporting.
• High concentration of credit risk with a few major customers and suppliers, making the company vulnerable to changes in their business relationships or financial health.
• The company has not completed its evaluation of Net Operating Loss (NOL) utilization limitations under Internal Revenue Code Section 382/383, which could limit or eliminate the benefit of approximately $48.8 million to $50.8 million in NOL carryforwards.
• The loan receivable from a related party of $4.41 million is due by December 31, 2025, and non-repayment would result in the borrower pledging stock as security, which could have implications for the company's assets.
• The $2 million and $6 million loans are now subordinated debt with repayment contingent on specific conditions (Liquidity, Fixed Charge Coverage Ratio, Consolidated Senior Net Leverage Ratio), introducing uncertainty regarding their repayment.
• The company is subject to customary representations, warranties, and covenants under its new $17.5 million term loan, including financial ratios, and a breach could trigger an event of default.
• The outcome of litigation is inherently uncertain, and while no material legal proceedings are currently identified, future proceedings could have an adverse impact.
• The company relies on estimates and assumptions in preparing financial statements, and actual results could differ.
• No material changes to previously disclosed risk factors in the Prospectus were identified in this quarterly report, implying that those existing risks remain relevant.

Future Outlook

Synergy CHC Corp. plans to organically grow its current product lines by developing and launching new products and expanding into new markets, including increased distribution for its FOCUSfactor ready-to-drink beverage and expansion into Mexico. The company also intends to pursue further strategic acquisitions that align with its brand portfolio.

Management Comments

• We focused on developing our currently owned brands into new markets and by product extensions.
• Our objective is to grow our two targeted verticals (Nutraceuticals and Ready To Drinks (RTDs)) to provide a balanced and synergistic portfolio that drives consumer demand via multiple channels.
• The increase in gross profit is directly related to the product mix sold.
• The increase in gross profit is related to the license revenue.
• The increase [in G&A] is primarily due to public market expenses.
• The increase [in interest expense] is primarily due to the advance and the amortization of original debt discount on the new loan.
• The increase [in interest expense] is primarily due to an advance taken in 2025, shares issued related to the modification of notes payable and new May 2025 loan.
• Our net income for the three months ended September 30, 2025, was $125,327 as compared to a net income of $783,593 for the three months ended September 30, 2024 due to other income in 2024 and higher expenses in 2025.
• Our net income for the nine months ended September 30, 2025, was $2,474,827 as compared to a net income of $2,019,309 for the nine months ended September 30, 2024 due to a gain on loan settlements.
• Management believes that there are no current legal matters that would have a material effect on the Company’s financial position or results of operations.
• Our Chief Executive Officer and our Chief Financial Officer, concluded that as of the end of the period covered by this Quarterly Report, (i) the Company’s disclosure controls and procedures were not effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the Commission), and (ii) the Company’s controls and procedures have not been designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Industry Context

Synergy CHC Corp. operates in the consumer health care, beauty, and lifestyle products industry, focusing on nutraceuticals and ready-to-drink beverages. The company's strategy of organic growth through new product development and market expansion, alongside strategic acquisitions, aligns with broader trends in the health and wellness sector where companies seek to diversify portfolios and reach new consumer bases. The expansion into Mexico indicates a pursuit of international growth opportunities, a common strategy for consumer brands.

Corporate Governance

Legal Proceedings

• No material legal proceedings are currently identified, though the company may be involved in litigation incident to the ordinary course of business, with outcomes inherently uncertain.

Related Party Transactions

• Loan receivable from a related party (company owned by CEO Jack Ross) of $4,407,449 as of September 30, 2025, due by December 31, 2025. If not repaid, the borrower will pledge stock as security.
• Prepaid consulting fees of $933,303 as of September 30, 2025, to a company owned by CEO Jack Ross.
• Prepaid rent of $116,909 as of September 30, 2025, to a company owned by CEO Jack Ross.
• Repaid $135,000 advance from a related party during the nine months ended September 30, 2025.
• Settled a $12,713,858 loan with Knight Therapeutics Inc., a shareholder, through cash, early payment discount, and equity conversion (issuance of pre-funded warrants).
• Expensed royalties of $10,488 for the nine months ended September 30, 2025, to Knight Therapeutics Inc. for distribution rights of FOCUSfactor in Canada.
• Issued 441,178 shares valued at $847,062 to a lender to release CEO Jack Ross from a personal obligation to grant warrants.
• Granted options to purchase 750,000 shares to a company owned by CEO Jack Ross.

Stakeholder Impact

• Shareholders: The IPO and debt reduction efforts could be seen positively, improving the balance sheet and providing capital for growth. However, the decrease in Q3 net income and the ineffective disclosure controls could raise concerns. The issuance of shares for debt settlement and consulting services dilutes existing shareholders.
• Creditors: Significant debt repayments and settlements, along with securing a new senior loan, improve the company's debt profile and liquidity, which is positive for creditors. The subordination of certain older loans to the new senior lender impacts their repayment priority.
• Employees: The granting of stock options to employees could serve as an incentive and retention tool.
• Customers: Continued focus on developing new products and expanding into new markets (e.g., FOCUSfactor RTD, Mexico) aims to enhance product offerings and availability.
• Suppliers: Settlement of loans with former suppliers indicates resolution of past obligations. High concentration of suppliers suggests reliance on a few key relationships.

Next Steps

• Organically grow current product lines.
• Develop and launch new products.
• Expand into new markets.
• Increase distribution for FOCUSfactor ready-to-drink beverage.
• Evaluate opportunities for additional strategic acquisitions.
• Repay related party loan receivable of $4,407,449 by December 31, 2025.
• Make quarterly repayments of $175,000 on the $17.5 million term loan starting January 1, 2026, increasing to $350,000 quarterly from January 1, 2027.

Key Dates

Recommendation

While Synergy CHC Corp. has made significant strides in strengthening its balance sheet through debt reduction, successful IPO, and securing new financing, several factors warrant a 'hold' recommendation. The substantial improvement in net income for the nine-month period is largely driven by non-recurring gains on debt settlements, masking a decline in Q3 net income due to higher expenses. The acknowledged ineffectiveness of disclosure controls and procedures is a serious concern that could impact investor confidence and future financial reporting reliability. Furthermore, the high concentration of revenue and accounts receivable with a few customers, and the outstanding related-party loan to the CEO's company, introduce additional risks. The company's strategic initiatives for growth are positive, but the execution risks and internal control deficiencies suggest a cautious approach until these issues are demonstrably resolved and sustainable organic growth is clearly established.

Keywords

Consumer Health, Nutraceuticals, FOCUSfactor, Flat Tummy, SEC Filing, 10-Q, Quarterly Report, Financial Results, Debt Settlement, IPO, Capital Raise, Corporate Governance, Risk Management, SYNERGY CHC CORP, SNYR, Nasdaq, Financial Performance, EBITDA, Product Sales, License Revenue, Working Capital, Strategic Acquisitions, Disclosure Controls